Senores Pharmaceuticals Ltd. Financials: Quarterly Results
Revenue
168.63
Cr.
PAT
33.58
Cr.
EBITDA
49.93
Cr.
Senores Pharmaceuticals Ltd. Q3FY26 Financial Metrics
| Indicator | Dec-25 | Sep-25 | Jun-25 | Mar-25 | Dec-24 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 164.85 | 153.36 | 130.30 | 114.21 | 103.02 |
| Total Income From Operations (Cr.) | 174.56 | 161.76 | 137.99 | 114.21 | 103.02 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | 49.93 | 46.82 | 31.53 | 25.98 | 26.65 |
| P/L Before Exceptional Items & Tax (Cr.) | 44.60 | 40.63 | 26.49 | 20.68 | 20.49 |
| P/L After Tax from Ordinary Activities (Cr.) | 33.58 | 30.12 | 21.18 | 17.97 | 16.43 |
| Net Profit/Loss For the Period (Cr.) | 33.58 | 30.12 | 21.18 | 17.97 | 16.43 |
| Basic EPS | 7.29 | 6.54 | 4.60 | 3.81 | 5.04 |
FAQs
Senores Pharmaceuticals Ltd. announced its quarterly results for Q3 FY2026 on January 20, 2026.
In Q3 FY2026, Senores Pharmaceuticals Ltd. are as follows:
Revenue: ₹168.63 crore
Net Profit: ₹33.58 crore.
For Q3 FY2026, Senores Pharmaceuticals Ltd. posted ₹168.63 crore in revenue and ₹33.58 crore in net profit.
Past quarterly results for Senores Pharmaceuticals Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.